

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書 籍 名	出版社名	出版地	出版年	ページ
日本腎臓学会		丸山彰一	CKD診療ガイド2024	東京医学社	東京	2024	

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Nyma Z, et al.	Evaluating the associations between compliance with CKD guideline component metrics and renal outcomes.	Sci Rep	14	11481	2024
Okada H, et al.	Development of a prognostic risk score to predict early mortality in incident elderly Japanese hemodialysis patients.	PLoS One	19	e0302101	2024
岡田浩一	特集：病診連携と多職種で取り組む日本のCKD対策 CKDの疾患概念とその臨床的重要性	日医会誌	153	385-388	2024
岡田浩一	特集：CKD対策の現在地 日本腎臓病協会・CKD対策研究班の協力体制とCKD対策	日腎会誌	(in press)	(in press)	(in press)
Kitai T, Maruyama S, Kuwahara K, Tamura K, Kinugawa K, Kashihara N.	Establishing Cross-Specialty Expert Consensus on the Optimal Management of Hyperkalemia in Patients With Heart Failure and Chronic Kidney Disease.	Circ J.	89(4)	470-478	2025
Kashihara N, Okada H, Suzuki Y, et al.	Efficacy and safety of patiromer for hyperkalemia: a randomized, placebo-controlled phase 3 study.	Clin Exp Nephrol.	Online ahead of print		2025

Johannes CB, Ziemiecki R, Pladivall-Vila M, et al.	Clinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor: A Multi-cohort Study.	Diabetes Ther.	16(2)	205-226	2025
Mondal R, Rituraj B, Kitaoka K, et al.	Oral microbiome alpha diversity and all-cause, cardiovascular, and non-cardiovascular mortality in US adults: Evidence from the NHANES 2009-2019.	Atherosclerosis.	401	119074	2025
Pollock C, Carrero JJ, Kanda E, et al.	Baseline Characteristics of the DISCOVER CKD Prospective Cohort.	Adv Ther.	42(3)	1393-1418	2025
Perkovic V, Barratt J, Rovin B, Kashihara N, et al.	Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy.	N Engl J Med.	392(6)	531-543	2025
Ohashi M, Ishikawa Y, Arai S, et al.	Comparative analysis of kidney function prediction: traditional statistical methods vs. deep learning techniques.	Clin Exp Nephrol.	Online ahead of print.		2025
Asahi K, Konta T, Tamura K, et al.	The health-economic impact of urine albumin-to-creatinine ratio testing for chronic kidney disease in Japanese patients with type 2 diabetes.	J Diabetes Investig.	16(1)	108-119	2025
Konta T, Asahi K, Tamura K, et al.	The health-economic impact of urine albumin-to-creatinine ratio testing for chronic kidney disease in Japanese non-diabetic patients.	Clin Exp Nephrol.	Online ahead of print.		2024
Heerspink HJL, Perkovic V, Tuttle KR, et al.	Selonsertib in Patients with Diabetic Kidney Disease: A Phase 2b Randomized Active Run-In Clinical Trial.	J Am Soc Nephrol.	35(12)	1726-1736.	2024

Shimamoto S, Nakahara T, Yamada S, Nagasu H, et al.	Association between proteinuria and mineral metabolism disorders in chronic kidney disease: the Japan chronic kidney disease database extension (J-CKD-DB-Ex).	Sci Rep.	28(8)	784-792	2024
Umebayashi R, Matsuoaka-Uchiyama N, Sugiyama H, et al.	The Change in Public Perception and Knowledge Acquisition Methods of Chronic Kidney Disease Among General Population in Okayama Prefecture, Japan.	Diseases.	12(11)	268	2024
Kishi S, Kadoya H, Kashiwara N.	Treatment of chronic kidney disease in older populations.	Nat Rev Nephrol.	20(9)	586-602	2024
Aoki R, Nihei Y, Matsuzaki K, et al.	Gross Hematuria after the COVID-19 mRNA Vaccination: Nationwide Multicenter Prospective Cohort Study in Japan.	Kidney360.	5(9)	1322-1332	2024
Sugawara Y, Kanda E, Hamano T, et al.	Guidelines for clinical evaluation of chronic kidney disease in early stages : AMED research on regulatory science of pharmaceuticals and medical devices.	Clin Exp Nephrol.	28(9)	847-865	2024
Pollock C, Carrero JJ, Kanda E, et al.	The Lived Experience of Patients with Chronic Kidney Disease: Insights From DISCOVER CKD.	Am J Nephrol.	55(6)	618-628	2024
Fishbane S, Carrero JJ, Kumar S, et al.	Hyperkalemia Burden and Treatment Pathways in Patients with CKD: Findings From the DISCOVER CKD Retrospective Cohort.	Kidney360.	5(7)	974-986	2024
Kanaoka T, Waki H, Yano Y, Nagasu H, et al.	J-CKD-DB investigators. Factors affecting the sodium-glucose cotransporter 2	Diabetes Obes Metab.	26(7)	2905-2914	2024

Nangaku M, Herrington WG, Goto S, et al.	Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA-KIDNEY.	Clin Exp Nephrol.	28(6)	588-595	2024
Kitaoka K, Yano Y, Nagasu H, et al.	Kidney outcomes of SGLT2 inhibitors among older patients with diabetic kidney disease in real-world clinical practice: the Japan Chronic Kidney Disease Database Ex.	BMJ Open Diabetes Res Care.	12(3)	e004115	2024
Waki K, Nara M, Enomoto S, et al.	Effectiveness of DiabetesPlus, a self-management support system for diabetic kidney disease: Randomized controlled trial.	NPJ Digit Med.	7(1)	104	2024
Yusei O, et al.	A case series of Fabry diseases with CKD in Japan.	Clin Exp Nephrol.	28(5)	404-408	2024
柏原 直樹	NP0法人日本腎臓病協会の取り組み.	日本医師会雑誌	153(4)	393-396	2024
岡田浩一, 柏原直樹, 栗原孝成, 小林一雄.	日本のCKD対策に今, 何が必要か.	日本医師会雑誌	153(4)	369-382	2024
角谷裕之, 柏原直樹.	今, なぜ, 透析医療と臨床倫理なのか? AMED CKMガイド2022から日本透析医学会の提言2020を倫理的に読み解く.	臨床透析	40(10)	1261-1265	2024
柏原直樹.	高齢化社会における腎臓病診療.	日本腎臓学会誌	66(2)	351-356	2024
Usui J, Hirayama K, Kobayashi M, Suzuki S, Ebihara I, Nishiki K, Mase K, Hirayama A, Saito C, Goto M, Koyama A, Yamagata K.	Randomized Prospective Controlled Open-labeled Trial of Cyclosporine with/without Low-dose Oral Corticosteroids in Idiopathic Membranous Nephropathy in Adults with Nephrotic Syndrome.	Intern Med.	Epub ahead of print.		2025

Nakamura H, Okubo R, Kumagai M, Anayama M, Makino Y, Tamura K, Nagasawa M, Okada H, Maruyama S, Hoshino J, Wada T, Narita I, Yamagata K.	Exploring factors associated with Kidney Disease Quality of Life in patients with advanced chronic kidney disease: the Reach-J CKD cohort study.	Clin Exp Nephrol.			2025
Otake Y, Watanabe T, Konta T, Watanabe M, Asahi K, Yamagata K, Fujimoto S, Tsuruya K, Narita I, Kasahara M, Shibagaki Y, Iseki K, Moriyama T, Kondo M, Watanabe T.	Macrocytic anemia, kidney dysfunction, and mortality in general population: Japan specific health checkup study.	Sci Rep.	14(1)	32005	2024
Tsunoda R, Kume K, Kagawa R, Sedzuki M, Kitagawa H, Mase K, Yamagata K.	Machine-learning-based identification of patients with IgA nephropathy using a computerized medical billing database.	PLoS One.	19(12)	e0312915	2024
Okubo R, Ohigashi T, Kondo M, Tsunoda R, Kai H, Saito C, Hoshino J, Okada H, Narita I, Maruyama S, Wada T, Yamagata K.	Associations of anemia and iron deficiency with health-related quality of life in patients with chronic kidney disease stage G3b-5 in Japan: sub analysis of the Reach-J CKD cohort study.	BMC Nephrol.	25(1)	414	2024
Hoshino J, Ohigashi T, Tsunoda R, Ito Y, Kai H, Saito C, Okada H, Narita I, Maruyama S, Pisoni R, Pecoits-Filho R, Yamagata K.	Physical activity and renal outcome in diabetic and non-diabetic patients with chronic kidney disease stage G3b to G5.	Sci Rep.	14(1)	26378	2024
Kosugi T, et al.	Association of body indices with mortality in older population: Japan Specific Health Checkups (J-SHC) Study.	J Am Geriatr Soc.	Epub ahead of print.		2024

Takahashi-Kobayashi M, Kawanishi K, Usui J, Yamazaki S, Seshiyan SV, Yamagata K.	Does old-to-young kidney transplantation rejuvenate old donor kidneys?	Histol Histopathol.	Epub ahead of print.		2024
Kosugi T, et al.	Serum High-Density Lipoprotein Cholesterol Levels and the Risk of Kidney Function Decline: The Japan Specific Health Checkups (J-SHC) Study.	J Atheroscler Thromb.	Epub ahead of print.		2024
Akiyama T, et al.	Serum calciprotein particle-to-phosphate ratio as a predictor of cardiovascular events in incident hemodialysis patients.	Ther Apher Dial.	Epub ahead of print.		2024
Kanauchi N, Saito C, Nagai K, Yamada K, Kai H, Watanabe T, Narita I, Matsuno S, Makino H, Hishida A, Yamagata K.	Effective method for life-style modifications focused on dietary sodium intake in chronic kidney disease: sub-analysis of the FROM-J study.	BMC Nephrol.	25(1)	274	2024
Miura M, Kohzuki M, Saito C, Sekai S, Sugaya H, Koyama S, Matsui Y, Sakuma T, Ito O, Yamagata K.	Systemic Capillary Responses to Acute Exercise in Hypertensive Seniors: Insights from a Single-Center Pilot Study.	J Clin Med.	13(10)	2818	2024
Tamaki H, et al.	Pulse pressure modifies the association between diastolic blood pressure and decrease in kidney function: the Japan Specific Health Checkups Study.	Clin Kidney J.	17(6)	sfaf152	2024

Mori S, Kosaki K, Matsui M, Tanahashi K, Sugaya T, Iwazu Y, Kuro-O M, Saito C, Yamagata K, Maeda S.	Estimated proximal tubule fluid phosphate concentration and renal tubular damage biomarkers in early stages of chronic kidney disease.	J Ren Nutr.	Epub ahead of print.		2024
Prasad P, Yamagata K.	One Size Doesn't Fit All: Revisiting the Threshold, Target, and Type of Erythropoietin-Stimulating Agent Therapy in Anemia of CKD.	Kidney Int Rep.	9(7)	1954-1956	2024
Sofue T, Matsuzawa R, Nishiwaki H, Tsuchida Y, Kosaki K, Hoshino J, Narita I, Yamagata K.	Exercise instruction during haemodialysis treatment after changes to the insurance regime: a nationwide questionnaire survey in Japan.	Sci Rep.	14(1)	9171	2024
Matsumoto A, et al.	Cigarette smoking and progression of kidney dysfunction: a longitudinal cohort study.	Clin Exp Nephrol.	Epub ahead of print.		2024
Ishii R, et al.	Renal Hemodynamic and Functional Changes in ADPKD Patients.	Kidney360.	5(5)	724-731	2024
Imasawa H, et al.	Comprehensive review of mitochondrial nephropathy—a renal phenotype in mitochondrial disease: causative genes, clinical and pathological features, diagnosis, prognosis, and treatment.	Clin Exp Nephrol.	29	39-56	2025
今澤俊之	ミトコンドリア腎症	日内会誌	113	1439-1444	2024
Habuka M, Hosojima M, Yata Y, Kurumada K, Yamagiwa M, Yonezawa M, et al.	Fanconi syndrome with acute proximal tubular injury induced by a dietary supplement containing benfotiamine: a case series report.	BMC Nephrol.	25	446	2024

Wakasugi M, Gotō S.	An increasing trend of overweight and obesity in the Japanese incident end-stage kidney disease population.	Nephrology (Carlton).	29	884-894	2024
Mitsuboshi S, Morizumi M, Kotake K, Kaseda R, Narita I.	Individual dipeptidyl peptidase-4 inhibitors and acute kidney injury in patients with type 2 diabetes: A systematic review and network meta-analysis.	Basic Clin Pharmacol Toxicol.	135	71-80	2024
Mitsuboshi S, Morizumi M, Kotake K, Kaseda R, Narita I.	Urate-Lowering Drugs and Muscle Injury: A Systematic Review and Network Meta-Analysis.	J Clin Pharmacol.	64	288-299	2024
Shirai N, Yamamoto S, Osawa Y, Tsubaki A, Morishita S, Murayama T, et al.	Protein intake and its relationship with frailty in chronic kidney disease.	Clin Exp Nephrol.	28	447-453	2024
Shirai N, Yamamoto S, Osawa Y, Tsubaki A, Morishita S, Sugahara T, et al.	Low muscle strength and physical function contribute to falls in hemodialysis patients, but not muscle mass.	Clin Exp Nephrol.	28	67-74	2024
Wakasugi M, Narita I.	Trends in the Incidence of Renal Replacement Therapy Due to Rapidly Progressive Glomerulonephritis in Japan, 2006-2021.	Intern Med.	63	2751-2755	2024
Wakasugi M, Yokoseki A, Wada M, Yoshino T, Momotsu T, Sato K, et al.	Cataract Surgery and Chronic Kidney Disease: A Hospital-based Prospective Cohort Study.	Intern Med.	63	1207-1216	2024
Kabasawa K, Takachi R, Hosojima M, Komata T, Nakamura K, Sawada N, et al.	Association of Protein Intake With Discordance Between Cystatin C- and Creatinine-Based Estimated Glomerular Filtration Rates in Community-dwelling Japanese Adults.	J Ren Nutr.	(in press)	(in press)	(in press)

猪阪 善隆	日本のCKD患者数の概算	日本医師会雑誌	7	384	2024
猪阪 善隆	大阪府内科医会会員におけるCKD関連新規治療薬に関する実態調査	大阪府内科医会誌	33	76-82	2024
Yasui S, Horino T, Mitani K, Terada Y, Okuhara Y, Hatakeyama Y.	Effect of age, sex, and chronic kidney disease on urinary creatinine excretion in Japanese patients.	Clin Exp Nephrol.	29	83-90	2025
Hatakeyama Y, Horino T, Yasui S, Terada Y, Okuhara Y.	Differences in characteristics and risk factors for acute kidney injury between elderly and very elderly patients: a retrospective review.	Clin Exp Nephrol.	28	1097-1110	2024
Horino T, Inotani S, Komori M, Ohnishi H, Terada Y.	Neuropsychiatric Systemic Lupus Erythematosus in a Patient with Pancytopenia and Chronic Schizophrenia Requiring Hospitalisation.	Intern Med.	64	147-151	2025
Osakabe Y, et al.	Clinical significance of amphiregulin in patients with chronic kidney disease.	Clin Exp Nephrol	28	421-430	2024
Funakoshi S, et al.	Hypopituitarism due to CNS Aspergillus Infection.	Intern Med.	63	2953-2959	2024
Kuwabara T, et al.	Survey of renal Biopsy registry database and Anticancer drug therapy in Japan (SUBARU-J study) .	Clin Kidney J.	17	327	2024
Mukoyama M, Kuwabara T.	Pre-dialysis blood pressure and cardiovascular mortality in Japan: Need for much stricter control?	Hypertens Res	47	811-812	2024
Abe M, Hatta T, Imamura Y, Sakurada T, Kaname S	Examine the optimal multidisciplinary care teams for patients with chronic kidney disease from a nationwide cohort study.	Kidney Res Clin Pract	44	249-264	2025

Sada KE, Nagasaka K, Kaname S, Nango E, Kishibe K, Dobashi H, Hiromura K, Kawakami T, Bandono M, Wada T, Arimura K, Murakawa Y, Harigai M	Clinical practice guidelines of the Japanese Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of microscopic polyangiitis and granulomatosis with polyangiitis: The 2023 update-secondary publication.	Mod Rheumatol	34	559-567	2024
Sada KE, Nagasaka K, Kaname S, Higuchi T, Furuta S, Nanki T, Tsuboi N, Arimura K, Dobashi H, Hiromura K, Bandono M, Wada T, Arimura Y, Maki no H, Harigai M.	Evaluation of Ministry of Health, Labour and Welfare diagnostic criteria for antineutrophil cytoplasmic antibody-associated vasculitis compared to ACR/EULAR 2022 classification criteria.	Mod Rheumatol	34	551-558	2024
Maruyama S, Ikeda Y, Kaname S, Kato N, Matsumoto M, Ishikawa Y, Shimono A, Miyakawa Y, Nanpaku M, Shibagaki Y, Okada H.	Ecilizumab for adult patients with atypical haemolytic-uraemic syndrome: full dataset analysis of Japanese post-marketing surveillance.	J Nephrol	37	2181-2190	2024
Nagase M, et al.	Glomerular endothelial cell receptor adhesion G-protein-coupled receptor F5 (ADGRF5) and the integrity of the glomerular filtration barrier.	J Am Soc Nephrol	35	1366-1380	2024
Kawazoe M, et al.	Nationwide epidemiological survey of polyarteritis nodosa in Japan in 2020.	Mod Rheumatol	34	1284-1287	2024
Katsumata Y, et al.	Comparison of different ANCA detection methods in a predominantly MPO-ANCA-associated vasculitis cohort.	Immunol Med	48	47-57	2025

Kaname S, Ong M-L, Mathiasc J, Gattad F, Lawe L, Wang Y	Outcomes in patients with thrombotic microangiopathy associated with a trigger following plasma exchange: a systematic literature review.	Transfus Apher Sci	64	104048	2024
要 伸也	CKD対策における多職種ケアの重要性. 特集: 病診連携と多職種で取り組む日本のCKD対策.	日本医師会雑誌	153	407-411	2024
要 伸也	慢性腎臓病に対するチーム医療と慢性腎臓病透析予防指導管理料の新設.	日本透析医学会雑誌	39	472-479	2024
中川 直樹	CKD対策における健診受診と受診勧奨の重要性	日本医師会雑誌	153巻4号	413-416	2024
Matsuoka-Uchiyama N, et al.	The association of fasting triglyceride variability with renal dysfunction and proteinuria in medical checkup participants.	Clin Exp Nephrol	Epub ahead of print.	Epub ahead of print.	Epub ahead of print.
Umebayashi R, Matsuoka-Uchiyama N, Sugiyama H, Shikata K, Kashihara N, Makino H, Wada J, Uchida HA.	The Change in Public Perception and Knowledge Acquisition Methods of Chronic Kidney Disease Among General Population in Okayama Prefecture, Japan.	Diseases	12(11)	268	2024
旭浩一	日本のCKD対策の進捗状況と展望	日本医師会雑誌	153	397-401	2024
Kuwabara T, Miyasato Y, Mukoyama M, et al.	Survey of renal Biopsy registry database and Anticancer drug therapy in Japan (SUBARU-J study).	Clin Kidney J.	17 (12)	sfae327	2024
Yamamoto T, Kashihara M, Mukoyama M, et al.	Multicenter randomized controlled trial of intensive uric acid lowering therapy for CKD patients with hyperuricemia: TARGET-UA.	Clin Exp Nephrol.	28 (8)	764-772	2024

Mukoyama M.	Fetal origins of adult hypertension and renal injury: an epigenetic memory matter?	Hypertens Res	47 (10)	2942-2944	2024
Mukoyama M.	Treatment with a mineralocorticoid receptor blocker esaxerenone on top of the first-line therapy: promise in uncontrolled hypertension.	Hypertens Res	47 (12)	3492-3493	2024
Morita H, Abe M, Mukoyama M, et al.	Resistance exercise has a sufficient antihypertensive effect comparable to aerobic exercise in hypertensive patients: a meta-analysis of randomized controlled trials.	Hypertens Res	48 (2)	733-743	2025
Suematsu Y, Morita H, Mukoyama M, et al.	Differences in the effects of exercise on blood pressure depending on the physical condition of the subject and the type of exercise: a systematic review and meta-analysis.	Hypertens Res	48 (2)	720-732	2025
Mayne KJ, Sardinelli RJ, Staplin N, et al.	Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.	Clin J Am Soc Nephrol	19	1119-1129	2024
Nakahara E, Wakai K, Kurasawa H, et al.	Predicting rapid decline in kidney function among type 2 diabetes patients: A machine learning approach.	Heliyon	11	e40566	2024
Erickson RL, Kamath N, Iyengar A, et al.	Disparities in kidney care in vulnerable populations: A multinational study from the ISN-GKHA.	PLOS Global Public Health	4	e0004086	2024

Azegami T, Kane ko H, Okada A, et al.	Association of Estim ated Glomerular Fil tration Ratio with th e Incidence of Sleep Apnea Syndrome.	Sleep	[Online ah ead of pri nt]	[Online ah ead of pri nt]	[Online ahea d of print]
Nishi H, Nangak u M, Sofue T, et al.	N-terminal pro-brain natriuretic peptide il and cardiorenal out come in patients wit h anaemia in chronic kidney disease.	ESC Heart Fa il	[Online ahead of print]	[Online ahead of print]	[Online ahead of print]
Kotwal SS, Perk ovic V, Jardine MJ, et al.	The Global Kidney Pa tient Trials Network and the CAPTIVATE P latform Clinical Tri al Design: A Trial P rotocol.	JAMA Netw Op en	7	e2449998	2024
Garcia P, Stras ma AK, Wijewick rama E, et al.	Regional hotspots fo r chronic kidney dis ease: A multinationa l study from the ISN -GKHA.	PLOS Glob Pu blic Health	4	e0004014	2024
Nkunu V, Tungsa nga S, Diongole HM, et al.	Landscape of kidney replacement therapy provision in low- an d lower-middle incom e countries: A multi national study from the ISN-GKHA.	PLOS Glob Pu blic Health	4	e0003979	2024
Okada A, Aso S, Kurakawa KI, et al.	Adding biomarker cha nge information to t he kidney failure ri sk equation improves predictive ability for dialysis depende ncy in eGFR <30 ml/m in/1.73 m ² .	Clin Kidney J	17	sfaf321	2024
Wainstein M, Ti v S, Arruebo S, et al.	Global Policy and Ad vocacy Initiatives f or Improving Kidney Care: Report from th e 2023 ISN-GKHA Stud y.	Kidney360	[Online ahead of print]	[Online ahead of print]	[Online ahead of print]
Judge PK, Tuttl e KR, Staplin N, et al.	The potential for im proving cardio-renal outcomes in chronic kidney disease with the aldosterone syn thase inhibitor vica drostat (BI 690517): a rationale for the EASi-KIDNEY trial.	Nephrol Dial Transplant	[Online ahead of print]	[Online ahead of print]	[Online ahead of print]

Herrington WG, Staplin N, Agrawal N, et al.	Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.	N Engl J Med	[Online ahead of print]	[Online ahead of print]	[Online ahead of print]
Wainstein M, Nandhu Y, Viecella A, et al.	A global snapshot on health systems capability for detection, monitoring, and management of acute kidney injury: A multinational study from the ISN-GKHA.	PLOS Glob Public Health	4	e0003823	2024
Okpechi IG, Levin A, Tungsanga S,	Progress of nations in the organisation of, and structures for, kidney care delivery between 2019 and 2023: cross sectional survey in 148 countries.	BMJ	387	e079937	2024
Ekrikpo UE, Davidson B, Caliceti-Silva V, et al.	Structures for quality assurance and measurements for kidney replacement therapies: A multinational study from the ISN-GKHA.	Nephrology	29	873-883	2024
Ko T, Kaneko H, Suzuki Y, et al.	Dose-dependent association between estimated glomerular filtration rate and the subsequent risk of depression: An analysis of a nationwide epidemiological dataset.	Eur J Clin Invest	55	e14322	2025
Mayne KJ, Sardehlil RJ, Staplin N, et al.	EMPA-KIDNEY Collaborative Group. Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.	Nephrol Dial Transplant	[Online ahead of print]	[Online ahead of print]	[Online ahead of print]
See E, Ethier I, Cho Y, et al.	Dialysis Outcomes Across Countries and Regions: A Global Perspective From the International Society of Nephrology Global Kidney Health Atlas Study.	Kidney Int Rep	9	2410-2419	2024

Jimba T, Kaneko H, Azegami T, et al.	Body weight change and associated kidney outcomes of sodium-glucose cotransporter new users.	Diabetes Obes Metab	26	4535-4543	2024
Suzuki Y, Kaneko H, Okada A, et al.	Kidney outcomes with SGLT2 inhibitor vs. DPP4 inhibitor use in older adults with diabetes.	Nephrol Dial Transplant	[Online ahead of print]	[Online ahead of print]	[Online ahead of print]
Kato S, Wang J, Onishi Y, Nangaku M.	Association between magnesium, erythropoietin resistance and mortality: the Japanese Dialysis Outcomes and Practice Patterns Study (J-DOPPS).	Clin Kidney J	17	sfael53	2024
Hanafusa N, Henrich L, Bieber B, et al.	Erythropoiesis-stimulating agent hyporesponsiveness was associated with worse survival of hemodialysis patients independent of the serum ferritin level.	Ther Apher Dial	[Online ahead of print]	[Online ahead of print]	[Online ahead of print]
Mayne KJ, Sardehlil RJ, Staplin N, et al.	EMPA-KIDNEY Collaborative Group. Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial.	Clin J Am Soc Nephrol	[Online ahead of print]	[Online ahead of print]	[Online ahead of print]
Azegami T, Kaneko H, Okada A,	Significance of eGFR and proteinuria for cardiovascular disease in individuals beyond 85 years.	Nephrol Dial Transplant	[Online ahead of print]	[Online ahead of print]	[Online ahead of print]
Heerspink HJL, Cherney D, Abdul Gafor AH, et al.	Effect of Avenciguat on Albuminuria in Patients with CKD: Two Randomized Placebo-Controlled Trials.	J Am Soc Nephrol	35	1227-1239	2024
Ghimire A, Shah S, Chauhan U, et al.	Global variations in funding and use of hemodialysis accesses: an international report using the ISN Global Kidney Health Atlas.	BMC Nephrol	25	159	2024

Higashihara T, Odawara M, Nishi H, et al.	Uremia Impedes Skeletal Myocyte Myomixer Expression and Fused Genic Activity: Implication for Uremic Sarcopenia.	Am J Pathol	194	759-771	2024
Lowe-Jones R, Elthier I, Fisher LA, et al.	Capacity for the management of kidney failure in the International Society of Nephrology North America and the Caribbean region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA).	Kidney Int Suppl	S13	97-109	2024
Pippas M, Alfanog G, Kelly DM, et al.	Regional Board and ISN-GKHA Team Authors. Capacity for the management of kidney failure in the International Society of Nephrology Western Europe region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA).	Kidney Int Suppl	S13	136-151	2024
Wing-Shing Fung W, Park HC, et al.	Regional Board and ISN-GKHA Team Authors. Capacity for the management of kidney failure in the International Society of Nephrology North and East Asia region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA).	Kidney Int Suppl	S13	97-109	2024
Calice-Silva V, Neyra JA, Ferrero Fuentes A, et al.	Regional Board and ISN-GKHA Team Authors. Capacity for the management of kidney failure in the International Society of Nephrology Eastern and Central Europe region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA).	Kidney Int Suppl	S13	29-42	2024

Karam S, Amouze gar A, Alshamsi IR, et al.	Capacity for the man agement of kidney fa ilure in the Interna tional Society of Ne phrology Middle East region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA).	Kidney Int S13 uppl	57-70	2024
Francis A, Wain stein M, Irish G, et al.	Capacity for the man agement of kidney fa ilure in the Interna tional Society of Ne phrology Oceania and South East Asia (OS EA) region: report f rom the 2023 ISN Glo bal Kidney Health At las (ISN-GKHA).	Kidney Int S13 uppl	110-122	2024
Prikhodina L, K omissarov K, Bu lanov N, et al.	Capacity for the man agement of kidney fa ilure in the Interna tional Society of Ne phrology Newly Indep endent States and Ru ssia region: report from the 2023 ISN Gl obal Kidney Health A tlas (ISN-GKHA).	Kidney Int S13 uppl	71-82	2024
Wijewickrama E, Alam MR, Bajpa i D, et al.	Regional Board and I SN-GKHA Team Author s. Capacity for the management of kidney failure in the Inte rnational Society of Nephrology South As ia region: report fr om the 2023 ISN Glob al Kidney Health Atl as (ISN-GKHA).	Kidney Int S13 uppl	123-135	2024
Tannor EK, Davi dson B, Nlandu Y, et al.	Regional Board and I SN-GKHA Team Author s. Capacity for the management of kidney failure in the Inte rnational Society of Nephrology Africa r egion: report from t he 2023 ISN Global K idney Atlas (ISN-GKH A).	Kidney Int S13 uppl	12-28	2024

Nangaku M, Ueta K, Nishimura K, et al.	Factors affecting responsiveness of vada dustat in patients with anemia associated with chronic kidney disease: a post-hoc subgroup analysis of Japanese phase 3 randomized studies.	Clin Exp Nephrol	28	391-403	2024
Suzuki Y, Kaneko H, Nagasawa H, et al.	Comparison of estimated glomerular filtration rate change with sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists among people with diabetes: A propensity-score matching study.	Diabetes Obesity Metabolism	26	2422-2430	2024
Sakashita M, Hamasaki Y, Okita R, et al.	Serum myostatin at dialysis initiation may predict 1-year mortality and hospitalization.	Nephron	148	544-552	2024
Bello AK, Okpechi IG, Levin A, et al.	ISN-GKHA Group. An update on the global disparities in kidney disease burden and care across world countries and regions.	Lancet Global Health	12	e382-e395	2024
Wanner C, Nankaku M, Kraus BJ, et al.	How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial.	Nephrology Dialysis Transplantation	39	1504-1513	2024
Tuttle KR, Hausheer SJ, Canziani ME, et al.	Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.	Lancet	403	379-390	2024

EMPA-KIDNEY Collaborative Group.	Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.	Lancet Diabetes Endocrinol	12	51-60	2024
Ikejiri K, Suzuki T, Muto S, et al.	Effects of NRF2 polymorphisms on safety and efficacy of bardoxolone methyl: subanalysis of TSUBAKI study.	Clin Exp Nephrol	28	225-234	2024
Okada A, Yamaguchi S, Imaizumi T, et al.	Modification effects of albuminuria on the association between kidney function and development of anemia in diabetes.	J Clin Endocrinol Metab	109	1012-1032	2024